Author:
Morgen E K,Lenz H-J,Jonker D J,Tu D,Milano G,Graziano F,Zalcberg J,Karapetis C S,Dobrovic A,O’Callaghan C J,Liu G
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology,Genetics,Molecular Medicine
Reference41 articles.
1. Donadon M, Ribero D, Morris-Stiff G, Abdalla EK, Vauthey J-N . New paradigm in the management of liver-only metastases from colorectal cancer. Gastrointest Cancer Res 2007; 1: 20–27.
2. Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au H-J et al. Cetuximab for the treatment of colorectal cancer. N Engl J Medicine 2007; 357: 2040–2048.
3. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011; 22: 1535–1546.
4. Soeda H, Shimodaira H, Watanabe M, Suzuki T, Gamoh M, Mori T et al. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer. Int J Clin Oncol 2013; 18: 670–677.
5. Custodio A . Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. Crit Rev Oncol/Hematol 2013; 85: 45–81.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献